Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26101415 | 1.00 | USP2 (0.39) | USP2TSHRCYP1A2SMN1; SMN2CYP2C9 | |
| SCHEMBL26102750 | 0.85 | USP2 (0.39) | USP2CYP1A2SMN1; SMN2CYP3A4MAPK1 | |
| SCHEMBL23981996 | 0.84 | SMN1; SMN2 (0.46) | USP2TSHRCYP1A2SMN1; SMN2CYP2C9 | |
| SCHEMBL23981666 | 0.83 | SLC6A9 (0.40) | USP2CYP1A2SMN1; SMN2CYP3A4MAPK1 | |
| SCHEMBL30396674 | 0.83 | SLC6A9 (0.40) | USP2CYP1A2SMN1; SMN2CYP3A4MAPK1 | |
| SCHEMBL30430227 | 0.80 | USP2 (0.57) | USP2TSHRCYP1A2SMN1; SMN2CYP2C9 | |
| SCHEMBL26103330 | 0.80 | RORC (0.47) | KDM1A | |
| SCHEMBL30429485 | 0.80 | EPHX2 (0.41) | USP2TSHRCYP1A2SMN1; SMN2CYP2C9 | |
| SCHEMBL26133816 | 0.80 | EPHX2 (0.41) | USP2TSHRCYP1A2SMN1; SMN2CYP2C9 | |
| SCHEMBL26103351 | 0.78 | L3MBTL3 (0.47) | SMN1; SMN2ALDH1A1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4423090-A2 | ANTAGONISTS OF GPR39 PROTEIN | Vasocardea, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076219-A2 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333405-A1 | ANTAGONISTS OF GPR39 PROTEIN | GPR39, GPR139, GPR119 | USP2 2263/4885TSHR 263/4885CYP1A2 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.